Tests a Chinese medical nutrition diet for type 2 diabetes and fatty liver
Tests a Chinese diet plan in adults with type 2 diabetes and fatty liver.
Plain-language title generated from the registry record
Registry title: Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
Key facts
- Where
- Changsha and Yichang, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and fatty liver disease (NAFLD). It tests a diet with intermittent energy restriction (the CMNT diet).
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes together with non-alcoholic fatty liver disease (NAFLD). Body mass index (BMI) above 18.0 kg/m2.
- Earlier treatment
- Weight stable for at least 3 months (gain or loss under 4kg (9 lb (4 kg))). Stable treatment for at least 3 months with 1-3 oral antidiabetic medications (with or without insulin), or no antidiabetic medication yet.
Main reasons for not taking part
- Heart disease, stroke or brain disease in the past 6 months or serious past brain or heart conditions listed in the record
- Liver cirrhosis, severe hepatitis, or severe liver or kidney disease
- Cancer within the past 5 years
- Diabetic ketoacidosis or hyperosmolar coma in the past 6 months, or 2 or more severe low blood sugar episodes in the past year
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Where in China
- Hunan Shanshui physical examination centerChangsha, ChinaTaking people
- Jinheyuan Outpatient Department, National Sub-health Intervention Technology Achievement Application CenterChangsha, ChinaTaking people
- Physical Examination Center of Gezhouba central hospital of SinopharmYichang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- State Key Laboratory of Subhealth Intervention Technology
- Trial code
- NCT07083336
- Record updated
- 24 July 2025
- Original description
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease. An interim analysis will be added to the planned 120-participant CMNT intervention program to compare intervention efficacy with the usual care control group and assess potential risks associated with dietary interventions.Read full original descriptionShow less
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease. An interim analysis will be added to the planned 120-participant CMNT intervention program to compare intervention efficacy with the usual care control group and assess potential risks associated with dietary interventions.
Inclusion: Patients diagnosed with type 2 diabetes and NAFLD; Age between 18 and 75 years; Body mass index (BMI) > 18.0 kg/m2; Weight stable for at least 3 months prior to the study (gain or loss <4kg); Stable treatment for at least 3 months with 1-3 oral; antidiabetic medications (with or without insulin therapy), or not yet receiving antidiabetic medication prior to the beginning of the study; Able to give written informed consent.
Exclusion: Use of any of the following medications or treatments:; Use of antihypertensive or lipid-lowering medications that have not reached a stable dosage before screening; Presence of any of the following medical histories or conditions:; History or presence of any cardiac disease within the past 6 months; Decompensated heart failure (NYHA Class III or IV); Unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stenting; History of hemorrhagic or ischemic stroke within the past 6 months, as assessed by the investigator as unsuitable for trial participation; Medical history of cerebral thrombosis, cerebral vascular blockage, encephalic angioma, transient ischemic attack, cerebral hemorrhage, stroke, hydrocephalus, or malignant brain tumor; History of carotid artery stenting; Urinary system conditions such as nephrotic syndrome, uremia, polycystic kidney disease, kidney transplantation, unilateral nephrectomy/congenital solitary kidney, renal atrophy, renal tumor; Digestive system conditions such as ascites, liver cirrhosis, liver fluke infection, severe hepatitis, gastric varices; Nervous system conditions such as cerebellar atrophy, demyelinating diseases, cerebral palsy, Parkinson's disease, mania, schizophrenia; Respiratory system conditions such as pulmonary embolism, cor pulmonale; Musculoskeletal system conditions such as arterial rupture, myeloma; Immune system conditions such as Behçet's disease, lupus erythematosus; Conditions such as chondrosarcoma, liposarcoma, brucellosis, leukemia; History of malignant tumor within the past 5 years, or currently under evaluation for potential malignancy; History of unstable or treatment-requiring proliferative retinopathy or macular edema within the past 6 months; History of diabetic ketoacidosis or hyperosmolar nonketotic diabetic coma within the past 6 months; Currently suffering from lower extremity arteriosclerotic occlusive disease; History of severe infection or severe trauma within the past 1 month; History of ≥2 severe hypoglycemic episodes within the past year; Currently suffering from clinically significant urinary tract/genital infection, or a history of complicated urinary tract infections, or recurrent urinary tract infections within the past 6 months; Currently suffering from uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening/baseline, or systolic blood pressure ≤90 mmHg and/or diastolic blood pressure ≤60 mmHg; History of other severe endocrine diseases, such as multiple endocrine neoplasia; History of severe hepatic or renal disease; Suspected or confirmed history of alcohol or drug abuse; Presence of severe psychiatric disorders or language barriers, unwillingness or inability to fully understand and cooperate; Any other conditions deemed unsuitable for trial participation by the investigator; Use of other medications that may affect glucose metabolism within the past 2 months, including systemic glucocorticoids (excluding inhaled or topical use), growth hormones, etc; Uncontrolled or severe arrhythmias (e.g., long QT syndrome), as assessed by the investigator as unsuitable for trial participation; Participants meeting any of the following criteria will not be allowed to participate in the trial:; Currently suffering from uncontrolled thyroid dysfunction; Blood donation or blood loss ≥400 mL within the past 3 months; Pregnant or breastfeeding women.